Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology announced new preliminary data from its Phase 2 SOLSTICE Hepatitis Delta trial. The data showed that Tobevibart, alone or combined with Elebsiran, was generally well tolerated and patients achieved high virologic response and ALT normalization.
June 05, 2024 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vir Biotechnology's Phase 2 SOLSTICE trial for Hepatitis Delta showed promising results with Tobevibart and Elebsiran, indicating high virologic response and ALT normalization.
The positive preliminary data from the Phase 2 SOLSTICE trial suggests that Vir Biotechnology's treatments for Hepatitis Delta are effective and well-tolerated. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100